Psychedelic therapeutics near first FDA approval as Compass Pathways and Definium report promising results

BioSpace notes that the psychedelic drug sector is regaining momentum after a setback in 2024 when Lykos’ MDMA therapy failed to win FDA clearance. The focus has shifted to new candidates, with Compass Pathways advancing a rolling FDA submission for its psilocybin‑based treatment, COMP360, aimed at patients with treatment‑resistant depression. Analysts expect the agency could grant approval by the end of the year if the data hold up.

Definium Therapeutics is also drawing attention after its LSD‑based therapy demonstrated strong efficacy in late‑stage trials for both depression and anxiety. The company reported a "profound" response in a recent depression study and a solid win in an anxiety trial just weeks later, suggesting the platform may be ready for broader development.

The sector received a further boost this summer when Eli Lilly announced a $3.8 billion purchase of AtaiBeckley, signaling major pharma confidence in psychedelic approaches. At the same time, public health figures are advocating for alternatives to traditional SSRIs, adding a potential market opening for these novel treatments.